Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics
This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described.
1. A method for treating a subject having a cancer associated with p53 having an aberrant conformation, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide represented by the sequence [L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 1).
2. The method of claim 1 , wherein the peptide is represented by the sequence [L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 1).
3. The method of claim 1 , wherein the peptide is represented by the sequence [L,Y,E,W] T R I T [L,Y] E (SEQ ID NO: 3).
4. The method of claim 1 , wherein the peptide consists of the sequence [L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 1).
5. The method of claim 1 , wherein the peptide consists of the sequence [L,Y,E,W] T R I T [L,Y] E (SEQ ID NO: 3).
6. The method of claim 1 , wherein the peptide comprises one of the following sequences:
(SEQ ID NO: 4)
LTRITLE
(SEQ ID NO: 5)
YTRITLE
(SEQ ID NO: 6)
ETRITLE
(SEQ ID NO: 7)
LTRIYLE
(SEQ ID NO: 8)
YTRIYLE
(SEQ ID NO: 9)
WTRITLE
(SEQ ID NO: 10)
WTRIYLE
(SEQ ID NO: 11)
ETRIYLE
(SEQ ID NO: 12)
LTKITLE
(SEQ ID NO: 13)
YTKITLE
(SEQ ID NO: 14)
WTKITLE
(SEQ ID NO: 15)
ETKITLE
(SEQ ID NO: 16)
LTKIYLE
(SEQ ID NO: 17)
YTKIYLE,
or
(SEQ ID NO: 18)
ETKIYLE.
7. The method of claim 1 , wherein the peptide is fused, optionally via a linker sequence, to a cell penetrating peptide (CPP).
8. The method of claim 1 , wherein the peptide is represented by the consensus sequence (R 1-16 )P I [L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 19).
9. The method of claim 1 , wherein the peptide is combined with a pharmaceutically acceptable carrier.
10. A method for treating a subject who has a mutant gene encoding p53 which imparts a susceptibility to develop cancers, comprising administering to the subject a plurality of doses comprising in total an effective amount of the pharmaceutical composition of a pharmaceutical composition comprising a peptide represented by the sequence [L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 1).
11. A method for treating a subject having a cancer associated with p53 having an aberrant conformation, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide represented by the sequence (R 2-16 ) P I (L/Y/E/W) T (R/K) I T L E (SEQ ID NO: 19), provided the sequence does not comprise YTRITLE (SEQ ID NO: 5).
12. The method of claim 11 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
13. The method of claim 11 , wherein the peptide comprises the amino acid sequence LTRITLE (SEQ ID NO: 4).
14. The method of claim 13 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
15. The method of claim 11 , wherein the peptide is coupled to 4 to 16arginine residues.
16. The method of claim 15 , wherein the peptide is coupled to the arginine residues by a peptide linker comprising 1-7 amino acids.
17. The method of claim 16 , wherein the peptide forms a polycationic structure.
18. The method of claim 16 , wherein the peptide forms an amphipathic structure.
19. The method of claim 16 , wherein the peptide is less than 30 amino acids in length.
20. The method of claim 14 , wherein the pharmaceutically acceptable carrier includes a peptide stabilizing excipient.
21. The method of claim 20 , wherein the peptide stabilizing excipient is a preservative that inhibits the growth of microorganisms.
22. The method of claim 11 , wherein the peptide comprises the sequence RRRRRRRRRRPILTRITLE (SEQ ID NO: 22).
23. The method of claim 11 , wherein the peptide comprises the sequence (R 2-16 ) P I L T R I T L E (SEQ ID NO: 19).
24. The method of claim 1 further comprising inhibiting proliferation of cancer cells or shrinking a tumor in the subject.
25. The method of claim 1 wherein the cancer is selected from ovarian cancer, breast cancer, colon carcinomas and basal cell carcinomas.
26. The method of claim 10 further comprising preventing the development of tumors in the subject.
27. A method of treating a subject having a tumor with aberrant p53 conformation, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide represented by the sequence [L,Y,E,W] T [R,K], I T [L,Y] E (SEQ ID NO: 1).
28. The method of claim 27 wherein the aberrant p53 conformation is aggregated p53 or misfolded p53.
29. The method of claim 28 wherein the composition lowers the amount of p53 aggregates, or restores the folding of a misfolded p53.
30. The method of claim 27 wherein the composition re-activates a biological or biochemical activity of p53 disrupted by the aberrant p53 conformation.